

FBRSL1 Antibody (C-term)

Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP11809b

Product Information

Application WB, FC, E **Primary Accession** Q9HCM7

Other Accession NP_001136113.1

Reactivity Human
Host Rabbit
Clonality Polyclonal
Isotype Rabbit IgG
Clone Names RB29571
Calculated MW 110907
Antigen Region 906-935

Additional Information

Gene ID 57666

Other Names Fibrosin-1-like protein, AUTS2-like protein, HBV X-transactivated gene 9

protein, HBV XAg-transactivated protein 9, FBRSL1, AUTS2L, KIAA1545, XTP9

Target/Specificity This FBRSL1 antibody is generated from rabbits immunized with a KLH

conjugated synthetic peptide between 906-935 amino acids from the

C-terminal region of human FBRSL1.

Dilution WB~~1:1000 FC~~1:10~50 E~~Use at an assay dependent concentration.

Format Purified polyclonal antibody supplied in PBS with 0.05% (V/V) Proclin 300. This

antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation

followed by dialysis against PBS.

Storage Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store

at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions FBRSL1 Antibody (C-term) is for research use only and not for use in

diagnostic or therapeutic procedures.

Protein Information


Name FBRSL1

Synonyms AUTS2L, KIAA1545, XTP9


References

Barcellos, L.F., et al. PLoS Genet. 5 (10), E1000696 (2009):

Images



All lanes: Anti-FBRSL1 Antibody (C-term) at 1:500 dilution + 293 whole cell lysate Lysates/proteins at 20 μ g per lane. Secondary: Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ASP1615) at 1/15000 dilution. Observed band size: 111 KDa Blocking/Dilution buffer: 5% NFDM/TBST.



FBRSL1 Antibody (C-term) (Cat. #AP11809b) flow cytometric analysis of K562 cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.